1. Home
  2. CLB vs IVA Comparison

CLB vs IVA Comparison

Compare CLB & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core Laboratories Inc.

CLB

Core Laboratories Inc.

HOLD

Current Price

$19.47

Market Cap

772.5M

Sector

N/A

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$6.52

Market Cap

804.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLB
IVA
Founded
1936
2011
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
772.5M
804.2M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
CLB
IVA
Price
$19.47
$6.52
Analyst Decision
Hold
Strong Buy
Analyst Count
2
9
Target Price
$12.50
$16.00
AVG Volume (30 Days)
361.0K
414.1K
Earning Date
02-04-2026
09-29-2025
Dividend Yield
0.21%
N/A
EPS Growth
25.86
N/A
EPS
0.68
N/A
Revenue
$517,501,999.00
$19,929,536.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.33
N/A
P/E Ratio
$28.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.72
$2.11
52 Week High
$20.82
$7.98

Technical Indicators

Market Signals
Indicator
CLB
IVA
Relative Strength Index (RSI) 74.09 78.22
Support Level $18.82 $4.48
Resistance Level $19.96 $5.17
Average True Range (ATR) 0.64 0.25
MACD 0.18 0.19
Stochastic Oscillator 88.35 94.28

Price Performance

Historical Comparison
CLB
IVA

About CLB Core Laboratories Inc.

Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: